{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:12:29Z","timestamp":1761894749448},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,7,31]],"date-time":"2008-07-31T00:00:00Z","timestamp":1217462400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1007\/s00277-008-0561-1","type":"journal-article","created":{"date-parts":[[2008,7,30]],"date-time":"2008-07-30T09:12:18Z","timestamp":1217409138000},"page":"67-71","source":"Crossref","is-referenced-by-count":40,"title":["Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone"],"prefix":"10.1007","volume":"88","author":[{"given":"Ulrike","family":"Klein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florentina","family":"Kosely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Hillenga\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hundemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Neben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Moehler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Hegenbart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony D.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,7,31]]},"reference":[{"issue":"4","key":"561_CR1","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1634\/theoncologist.8-4-381","volume":"8","author":"AK Kakkar","year":"2003","unstructured":"Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J (2003) Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 8(4):381\u2013388 doi: 10.1634\/theoncologist.8-4-381","journal-title":"Oncologist"},{"issue":"9109","key":"561_CR2","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0140-6736(97)10018-6","volume":"351","author":"JA Baron","year":"1998","unstructured":"Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M (1998) Venous thromboembolism and cancer. Lancet 351(9109):1077\u20131080 doi: 10.1016\/S0140-6736(97)10018-6","journal-title":"Lancet"},{"issue":"6","key":"561_CR3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","volume":"293","author":"JW Blom","year":"2005","unstructured":"Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293(6):715\u2013722 doi: 10.1001\/jama.293.6.715","journal-title":"JAMA"},{"issue":"1","key":"561_CR4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","volume":"21","author":"D Weber","year":"2003","unstructured":"Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21(1):16\u201319 doi: 10.1200\/JCO.2003.03.139","journal-title":"J Clin Oncol"},{"issue":"11","key":"561_CR5","first-page":"3377","volume":"8","author":"K Neben","year":"2002","unstructured":"Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD et al (2002) Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 8(11):3377\u20133382","journal-title":"Clin Cancer Res"},{"issue":"6","key":"561_CR6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","volume":"160","author":"JA Heit","year":"2000","unstructured":"Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case\u2013control study. Arch Intern Med 160(6):809\u2013815 doi: 10.1001\/archinte.160.6.809","journal-title":"Arch Intern Med"},{"issue":"5","key":"561_CR7","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","volume":"98","author":"M Zangari","year":"2001","unstructured":"Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV et al (2001) Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98(5):1614\u20131615 doi: 10.1182\/blood.V98.5.1614","journal-title":"Blood"},{"issue":"21","key":"561_CR8","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357(21):2133\u20132142 doi: 10.1056\/NEJMoa070596","journal-title":"N Engl J Med"},{"issue":"19","key":"561_CR9","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","volume":"354","author":"R Knight","year":"2006","unstructured":"Knight R, DeLap RJ, Zeldis JB (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354(19):2079\u20132080 doi: 10.1056\/NEJMc053530","journal-title":"N Engl J Med"},{"issue":"19","key":"561_CR10","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","volume":"354","author":"SV Rajkumar","year":"2006","unstructured":"Rajkumar SV, Blood E (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354(19):2079\u20132080 doi: 10.1056\/NEJMc053530","journal-title":"N Engl J Med"},{"issue":"21","key":"561_CR11","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357(21):2123\u20132132 doi: 10.1056\/NEJMoa070594","journal-title":"N Engl J Med"},{"key":"561_CR12","doi-asserted-by":"crossref","unstructured":"Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF, Whittenberger BF et al Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG Trial S0232. ASH Annual Meeting Abstracts 2007 November 16;110(11):77","DOI":"10.1182\/blood.V110.11.77.77"},{"issue":"8","key":"561_CR13","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1538-7836.2006.02059.x","volume":"4","author":"A Palumbo","year":"2006","unstructured":"Palumbo A, Rus C, Zeldis JB, Rodeghiero F, Boccadoro M (2006) Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost 4(8):1842\u20131845 doi: 10.1111\/j.1538-7836.2006.02059.x","journal-title":"J Thromb Haemost"},{"key":"561_CR14","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M, et al A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. ASH Annual Meeting Abstracts 2007 November 16;110(11):74","DOI":"10.1200\/jco.2008.26.15_suppl.8504"},{"issue":"5","key":"561_CR15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archinte.159.5.445","volume":"159","author":"JA Heit","year":"1999","unstructured":"Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III (1999) Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 159(5):445\u2013453 doi: 10.1001\/archinte.159.5.445","journal-title":"Arch Intern Med"},{"key":"561_CR16","doi-asserted-by":"crossref","unstructured":"Palumbo A, Cavo M, Bringhen S, Perrone G, Magarotto V, Patriarca F, et al Prospective, randomized, phase III study of enoxaparin versus aspirin versus low-fixed-dose of warfarin in newly diagnosed myeloma patients treated with thalidomide-containing regimens. ASH Annual Meeting Abstracts 2007 November 16;110(11):310.","DOI":"10.1182\/blood.V110.11.310.310"},{"key":"561_CR17","doi-asserted-by":"crossref","unstructured":"Wright JA, Weber D, Thomas SK, Wang M, Alexanian R, Hawkins VE, et al Characteristics of patients experiencing thromboembolic events during treatment for multiple myeloma: aspirin may not be adequate thromboprophylaxis in patients with multiple risk factors. ASH Annual Meeting Abstracts 2007 November 16;110(11):1882","DOI":"10.1182\/blood.V110.11.1882.1882"},{"issue":"2","key":"561_CR18","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San MJ, Barlogie B et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414\u2013423 doi: 10.1038\/sj.leu.2405062","journal-title":"Leukemia"},{"issue":"10","key":"561_CR19","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","volume":"110","author":"PG Richardson","year":"2007","unstructured":"Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T et al (2007) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110(10):3557\u20133560 doi: 10.1182\/blood-2006-08-036947","journal-title":"Blood"},{"issue":"11","key":"561_CR20","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1182\/blood.V108.11.3571.3571","volume":"108","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Richardson P, Palumbo A, Dimopoulos MA, Cavo M, Hajek R et al (2006) Deep vein thrombosis in myeloma: estimate of prevalence and recommendations for therapy based upon a survey of members of the International Myeloma Working Group (IMWG). Blood 108(11):3571 ASH Annual Meeting Abstracts","journal-title":"Blood"},{"issue":"Suppl 3","key":"561_CR21","doi-asserted-by":"crossref","first-page":"338S","DOI":"10.1378\/chest.126.3_suppl.338S","volume":"126","author":"WH Geerts","year":"2004","unstructured":"Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW et al (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(Suppl 3):338S\u2013400S doi: 10.1378\/chest.126.3_suppl.338S","journal-title":"Chest"},{"issue":"12","key":"561_CR22","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","volume":"80","author":"R Baz","year":"2005","unstructured":"Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E et al (2005) The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80(12):1568\u20131574","journal-title":"Mayo Clin Proc"},{"issue":"34","key":"561_CR23","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","volume":"25","author":"GH Lyman","year":"2007","unstructured":"Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M et al (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25(34):5490\u20135505 doi: 10.1200\/JCO.2007.14.1283","journal-title":"J Clin Oncol"},{"issue":"12","key":"561_CR24","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/sj.leu.2403533","volume":"18","author":"MC Minnema","year":"2004","unstructured":"Minnema MC, Breitkreutz I, Auwerda JJ, van der Holt B, Cremer FW, van Marion AMW, Westveer PHM, Sonneveld P, Goldschmidt H, Lokhorst HM (2004) Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 18(12):2044\u20132046 doi: 10.1038\/sj.leu.2403533","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-008-0561-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-008-0561-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-008-0561-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T10:19:36Z","timestamp":1588846776000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-008-0561-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,31]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["561"],"URL":"https:\/\/doi.org\/10.1007\/s00277-008-0561-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,31]]}}}